Skip to main content

Drug Interaction Report

1 potential interaction and/or warning found for the following 2 drugs:

Filter by interaction and/or warning

Interactions between your drugs

Minor

raloxifene datopotamab deruxtecan

Applies to: raloxifene, datopotamab deruxtecan

Raloxifene is more than 95% protein bound. Caution should be exercised if raloxifene is coadministered with other highly protein-bound drugs. The mechanism is displacement of the drug from its protein-binding site by raloxifene. Displacement may lead to increased free plasma concentrations and potentiate toxicity of drugs affected by raloxifene. Formal in-vitro studies indicate that raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. The clinician may want to use caution when raloxifene is used with other highly-protein bound drugs, such as diazepam, diazoxide, or lidocaine.

References (3)
  1. (2023) "Product Information. Evista (raloxifene)." Lilly, Eli and Company
  2. (2019) "Product Information. Raloxifene (raloxifene)." Aspire Pharma Ltd
  3. (2023) "Product Information. Evista (raloxifene)." Eli Lilly Australia Pty Ltd

Drug and food interactions

No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No duplication warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

See also:

Learn more

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.